Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery
Author(s) -
Mercedes GonzalezJuarrero,
Lisa K. Woolhiser,
Elizabeth J. Brooks,
Mary Ann DeGroote,
Anne J. Lenaerts
Publication year - 2012
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00464-12
Subject(s) - aerosolization , isoniazid , medicine , capreomycin , mycobacterium tuberculosis , pharmacology , ethambutol , amikacin , drug delivery , tuberculosis , drug , rifapentine , immunology , microbiology and biotechnology , antibiotics , latent tuberculosis , biology , pathology , inhalation , chemistry , anesthesia , organic chemistry
Here we describe an experimental murine model that allows for aerosolized antituberculosis drug efficacy testing. Intrapulmonary aerosol delivery of isoniazid, capreomycin, and amikacin to mice with pulmonary infection ofMycobacterium tuberculosis demonstrated efficacy in reducing pulmonary bacterial loads similar to that seen by standard drug delivery methods, even when lower concentrations of drugs and fewer doses were used in the aerosolized drug regimens. Interestingly, intrapulmonary delivery of isoniazid also reduced the bacterial load in the spleen.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom